Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

CStone presents updated results of a registrational study of sugemalimab in patients with stage III NSCLC via oral presentation at WCLC 2022

* GEMSTONE-301 study result was presented at IASLC 2022 World Conference on Lung Cancer. In addition, the leading Principal Investigator ProfessorYi-Long Wu was invited to highlight key data in a press conference * In the final progression-free survival analysis, sugemalimab showed sustained ...

2022-08-08 08:08 3654

Transcenta Announces the Appointment of Dr. Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer

SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces the appointment of Dr. ...

2022-08-08 08:00 3603

Innovent Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema

SAN FRANCISCO and SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2022-08-08 08:00 3982

BGI's Global Life Science Research Leadership Recognized in 2022 Nature Index

SHENZHEN, China, Aug. 5, 2022 /PRNewswire/ -- BGI's leading global position in life science research has been recognized in the 2022 Nature Index. BGI rose two places to 8th in the world among corporate institutions for its contribution to life science research and was the only Chinese corporate ...

2022-08-05 22:18 5907

Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China

* Collaboration to accelerate the development and access of oncology medicines for cancer patients inChina * Clinical trial programs combining two of Sanofi's prioritized oncology assets with sintilimab, the leading checkpoint inhibitor inChina, to address some of the most prevalent solid tum...

2022-08-04 23:30 5624

Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA

HANGZHOU, China and SHAOXING, China, Aug. 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the Investigational New Drug (IND) application of ASC10, an oral inhibitor drug candidate targeting RNA-dependent RNA polymerase (RdRp) for COVID-19, has been accep...

2022-08-04 08:10 4367

Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients

-- ASC10 is an oral double prodrug that is rapidly and completely converted in vivo into the active metabolite ASC10-A, which is the same active metabolite of molnupiravir -- Ascletis has filed multiple patent applications for ASC10 and its use globally. Compared with molnupiravir, ASC10 has a n...

2022-08-03 16:50 3702

Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines

TAIZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:02179.HK) is pleased to announce that, the Company has recently received the clinical trial approval for its recombinant protein COVID-19 vaccine,...

2022-08-03 13:09 4830

Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

* ATG-101 is a novel PD-L1/4-1BB bispecific antibody. It is Antengene's first in-house developed molecule with global rights. * ATG-101 demonstrates potent in vivo efficacy in anti-PD-1/PD-L1 resistant mouse tumor models. SHANGHAI and HONG KONG, Aug. 3, 2022 /PRNewswire/ -- Antengene Corpora...

2022-08-03 08:30 3014

Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China

- Robust HbA1c reduction of 2.4% was observed with 1.2 mg XW003 dose - Up to 88% of participants achieved HbA1c ≤ 7% and up to 72% achieved HbA1c ≤6.5% at the end of the 20-week treatment - XW003 was safe and well tolerated with gastrointestinal side effects as the most commonly reported adve...

2022-08-03 08:00 3630

Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China

HANGZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that its innovative drug LNK01004, has been approved by National Medical Products Administration (NMPA) for clinical tr...

2022-08-03 08:00 3970

Ablaze Pharma Aligned The Strategic Agreement With Wenjiang District Government of Chengdu to Build-up the Innovative R&D and Manufacturing Center for Targeted Radiopharmaceutical Therapies

SHANGHAI, Aug. 3, 2022 /PRNewswire/ -- In July 2022, Ablaze Pharma and Wenjiang District Government ofChengdu jointly signed the strategic agreement during the Conference of Major Advanced Manufacturing Projects by Foreign Direct Investment. About 26,000㎡ of industrial land is selected in the Che...

2022-08-03 08:00 3262

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA and FLORENCE, Italy, Aug. 2, 2022 /PRNewswire/ -- Context Therapeutics Inc. ("Context" or the "Company") (...

2022-08-02 22:49 4849

Metabolon Awarded ISO 9001:2015 Recertification

ISO 9001:2015 certificate re-issued to Metabolon following continued demonstrated ability to meet customer, statutory, and regulatory standards MORRISVILLE, N.C., Aug. 2, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and ...

2022-08-02 20:57 2203

Dr Ivan Puah Recommends Fat Grafting As A Solution Following Post-surgery Scars or Disfigurement

Fat grafting is highly recommended as part of the corrective surgery method to correct facial or body disfigurement from liposuction, laparoscopy or surgeries that cause dents and irregular contours. SINGAPORE, Aug. 2, 2022 /PRNewswire/ -- Dr Ivan Puah, Medical Director at Amaris B. Clinic,...

2022-08-02 16:41 3131

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Implemented by the Centers for Disease Control and Prevention, the diagnosis code will accurately identify US patients with APDS, supporting care and research efforts LEIDEN, Netherlands, Aug. 2, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Na...

2022-08-02 13:00 3890

GenKOre develops hypercompact adenine base editors (ABEs)

DAEJEON, South Korea, Aug. 2, 2022 /PRNewswire/ -- GenKOre, a biotech start-up in Korea, succeeded in the development of ABEs based on its own hypercompact gene-editing technology and had the relevant study published on Nature Chemical Biology onAugust 2, 2022.

2022-08-02 09:07 3538

GenKOre develops hypercompact adenine base editors (ABEs)

AVer Introduces Revolutionary Detachable Medical Grade Cameras

NEW TAIPEI CITY, Taiwan, Aug. 2, 2022 /PRNewswire/ -- AVer Information Inc., the award-winning provider of video collaboration and education technology solutions, is excited to introduce its Connected Health Solutions, which was created from AVer's dedication in understanding and contributing to ...

2022-08-02 09:00 3414

Kira Pharmaceuticals Appoints Angela Yan as President of China and Asia Development and Operations

CAMBRIDGE, Mass. and SUZHOU, China, Aug. 2, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global clinical-stage biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced the appointment ofAngela (Hui) Yan as President of China and Asi...

2022-08-02 07:00 4557

Kira Pharmaceuticals Appoints Angela Yan as President of China and Asia Development and Operations

Telix APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging

MELBOURNE, Australia, Aug. 2, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports on regulatory progress for the Company's core prostate and kidney cancer imaging programs in theAsia Pacific (APAC) Operating Region, including progress in the major marke...

2022-08-02 06:54 3165

1 ... 142 143 144145146 147 148 ... 184